23,99 €
inkl. MwSt.

Versandfertig in 6-10 Tagen
  • Broschiertes Buch

The antibiotic era proved a boon for mankind but, with the change in time various microbes develop resistance against antibiotics and it would decrease the effect of antimicrobial agents on resistant microbes. Thus, alternate strategies should be framed into mind to overcome this problem and new methods have been developed like nanoparticles as antimicrobials, new synthetic drugs and transition metal complexes. The development of novel class of antibiotics is time consuming and it is not as effective as of these new methods. Many transition metal complexes synthesis early possess antibacterial…mehr

Produktbeschreibung
The antibiotic era proved a boon for mankind but, with the change in time various microbes develop resistance against antibiotics and it would decrease the effect of antimicrobial agents on resistant microbes. Thus, alternate strategies should be framed into mind to overcome this problem and new methods have been developed like nanoparticles as antimicrobials, new synthetic drugs and transition metal complexes. The development of novel class of antibiotics is time consuming and it is not as effective as of these new methods. Many transition metal complexes synthesis early possess antibacterial activity and serves as a source of antimicrobial agent against various pathogenic microorganisms and they play key role in pharmaceutical industries for the development of various potential drugs against several harmful diseases. In present study the antibacterial activity of the transition metals were assessed against gram negative E.coli microorganism. Some of the transition metal compound shows antibacterial activity against this microorganism at varies dilutions and some do not show any activity.
Autorenporträt
I have done my masters in biotechnology and after completing my MSc I cleared DBT-BITP exam and pursued training in IPR as patent research analyst from US based company. Now, I am working as QA expert at Chegg and as a freelancer in IPR sector.